查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1820310

连网药物输送设备市场规模、份额、趋势及预测（按产品、最终用户、技术和地区），2025 年至 2033 年

Connected Drug Delivery Devices Market Size, Share, Trends, and Forecast by Product, End User, Technology, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球连网药物输送设备市场规模达10.8178亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到81.4287亿美元，2025年至2033年的复合年增长率为23.13%。目前，北美占据连网药物输送设备市场份额的主导地位，2024年的市占率将超过41.2%。该地区连网药物输送设备市场份额的成长得益于医疗技术的进步、连网设备的广泛普及、慢性病盛行率的上升以及支持性监管框架的完善。

新冠疫情加速了连网药物输送设备市场中远距医疗解决方案的采用。因此，医疗机构的患者就诊量也非常低。市场对可用于居家自我监测和药物管理的设备需求旺盛。这更强调了在居家照护环境中确保患者依从性和高效的治疗管理。疫情进一步推动了数位医疗技术的创新，远距医疗报销政策的完善也促进了连网药物输送设备的扩张。

气喘、糖尿病和心血管疾病等慢性疾病的盛行推动了对更有效率、更精准的药物传递方法的需求。连网药物传输设备可确保剂量准确，改善整体治疗效果，进而提供解决方案，使其成为长期健康状况管理的关键。此外，连网设备透过提供提醒、剂量追踪和通知等功能，有助于应对日益严重的服药不依从性问题。它们确保患者按时服药并遵循处方方案，这对于治疗效果至关重要。此外，感测器技术、无线通讯以及与行动应用程式和医疗平台整合方面的创新正在增强联网药物传输设备的功能。这些进步使设备能够提供更精准的追踪、监测和即时回馈，使其在临床和家庭环境中都具有极高的效率。

美国在互联药物输送设备市场份额中扮演着至关重要的角色，这得益于糖尿病、气喘和心血管疾病等慢性疾病的日益增长，这些疾病需要高效可靠的药物输送解决方案。互联药物传递设备透过确保精准剂量和增强服药顺从性，有助于改善疾病管理。此外，美国食品药物管理局 (FDA) 正在为互联医疗设备建立清晰的监管框架，鼓励创新和数位医疗解决方案的采用。此外，远距医疗和互联设备的报销政策不断扩大，有助于患者和医疗保健提供者更容易获得这些技术。 2024年，BIOCORP 宣布其 SoloSmart(R) 已获得 FDA 510(k) 批准，这是一款为赛诺菲 SoloStar 胰岛素笔开发的智慧感测器。该设备可追踪胰岛素单位、注射日期和时间，并将资讯发送到数位应用程序，从而改善糖尿病管理。这是 BIOCORP 的 Mallya 平台第二次获得 FDA 批准。

连网药物输送设备市场趋势：

人口老化日益加剧

随着人们老化，罹患糖尿病、高血压和心血管疾病等持续性疾病的风险也越来越大。连网药物传输设备在有效应对这些情况方面发挥着重要作用，它们能够确保精准的药物剂量和监测。此外，这些设备还可以透过提醒、剂量追踪和将记录自动传输给医疗保健公司来简化用药方案。连网药物传输设备可以远端追踪服药依从性和健康状况参数。这使得医疗保健公司能够及早干预这些问题，从而支持居家养老。世界卫生组织 (WHO) 网站上发表的一篇文章显示，到 2050 年，全球 60 岁以上人口预计将翻一番，达到近 21 亿。预计这将对产品需求产生积极影响，同时显着推动连网药物输送设备市场的成长。

慢性阻塞性肺病（COPD）盛行率上升

根据世界卫生组织 (WHO) 网站 2023 年更新的内容，70 岁以下人口中近 90% 的 COPD 死亡病例发生在中低收入国家。 COPD 患者需要精准且可控制的药物输送，包括支气管扩张剂和皮质类固醇。连网药物传输设备可确保正确剂量和及时给药，这对于有效应对 COPD 症状至关重要。此外，连网设备可以监测吸入策略并即时向患者提供回馈。这使得 COPD 患者能够优化吸入方案，确保他们从药物中获得最大益处。因此，COPD 是一种需要持续监测症状和肺功能的革命性疾病。连网设备可以远端监测 COPD 患者的健康状况，包括肺功能检查和症状监测，有助于及早发现病情恶化并及时调整治疗方案。

蓬勃发展的远距医疗产业

IMARC集团的报告显示，2023年全球远距医疗市场规模达747亿美元。远距医疗平台促进了医疗服务提供者与患者之间的远距会诊，为寻求医疗保健的个人提供了更大的可近性和便利性。连网药物输送设备可以即时追踪患者的服药依从性、治疗反应和整体健康状况，从而补充远距医疗。这些设备提供有关药物摄取、服药时间和患者状况的重要资料，这对于管理糖尿病、高血压和呼吸系统疾病等慢性疾病尤其有益。此外，连网药物传输设备与远距医疗平台的整合，使医疗服务提供者能够远端调整药物剂量、微调治疗方案并持续监测患者病情进展。这种协同作用不仅确保了更精准、更个人化的护理，还透过直接从患者环境中提供可操作的洞察，提高了远距医疗会诊的有效性。这种整合支持主动式管理，改善患者预后，减少频繁就诊的需求。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球连网药物输送设备市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品

  • 互联感测器
    • 关键部分
      • 联网吸入器感测器
      • 可连接的喷射感测器
  • 整合连接设备
    • 关键部分
      • 网路吸入设备
      • 连网注射设备

第七章：市场区隔：依最终用户

  • 医院和医疗保健提供者
  • 居家护理

第八章：市场区隔：依技术

  • 蓝牙
  • 近场通讯
  • 其他技术

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Adherium Limited
    • BioCorp Production
    • Cohero Health Inc. (AptarGroup Inc.)
    • Elcam Medical ACS. Ltd
    • Findair Sp. z oo
    • Merck KGaA
    • Phillips Medisize (Molex LLC)
    • Propeller Health (Resmed Inc.)
    • Teva Pharmaceutical Industries Ltd.
    • West Pharmaceutical Services Inc.
Product Code: SR112025A3738

The global connected drug delivery devices market size was valued at USD 1,081.78 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 8,142.87 Million by 2033, exhibiting a CAGR of 23.13% from 2025-2033. North America currently dominates the connected drug delivery devices market share, holding a market share of over 41.2% in 2024. The region's connected drug delivery devices market share is driven by advancements in healthcare technology, high adoption of connected devices, increasing chronic disease prevalence, and supportive regulatory frameworks.

The COVID-19 pandemic accelerated the adoption of remote healthcare solutions within the connected drug delivery devices market outlook. Due to this, the number of patient visitations in healthcare facilities was also very low. There was intense demand for devices that could be used for self-monitoring and self-management of medications at home. This placed emphasis on ensuring medication adherence and efficient treatment management in the home care setting. The pandemic boosted innovation in digital health technologies further, and growth in reimbursement policies for telehealth supported the expansion of connected drug delivery devices.

The prevalence of chronic conditions, which include asthma, diabetes, and cardiovascular diseases is driving the demand for more efficient and accurate medication delivery methods. Connected drug delivery devices offer a solution by ensuring proper dosing and improving overall treatment outcomes, making them essential for managing long-term health conditions. in addition, connected devices help address the growing challenge of medication non-adherence by offering features like reminders, dosage tracking, and notifications. They ensure that patients take their medications on time and follow prescribed regimens, which is crucial for the effectiveness of treatments. Moreover, innovation in sensor technology, wireless communication, and integration with mobile applications and healthcare platforms is enhancing the functionality of connected drug delivery devices. These advancements allow devices to provide more accurate tracking, monitoring, and real-time feedback, making them highly effective in both clinical and home settings.

The United States plays a crucial role in the connected drug delivery devices market share, driven by the rising prevalence of chronic diseases like diabetes, asthma, and cardiovascular conditions, which require efficient and reliable medication delivery solutions. Connected drug delivery devices help improve disease management by ensuring accurate dosing and enhancing medication adherence. Furthermore, the U.S. Food and Drug Administration (FDA) is establishing clear regulatory frameworks for connected medical devices, encouraging innovation and the adoption of digital health solutions. Additionally, expanding reimbursement policies for telehealth and connected devices are helping make these technologies more accessible to patients and healthcare providers. In 2024, BIOCORP revealed it obtained FDA 510(k) approval for SoloSmart(R), an intelligent sensor created for Sanofi's SoloStar insulin pens. The device tracks insulin units, injection date, and time, sending information to a digital app, improving diabetes management. This represents the second approval from the FDA for BIOCORP's Mallya platform.

Connected Drug Delivery Devices Market Trends:

Growing aging population

As people are aging, they are encountering greater risk of continual ailments like diabetes, high blood pressure, and cardiovascular diseases. Connected drug delivery devices play an important role in handling those situations effectively by ensuring precise medicinal drug dosing and monitoring. Moreover, these devices can simplify those regimens through reminders, tracking dosages, and transmitting records mechanically to healthcare companies. Connected drug delivery devices allow remote tracking of medicine adherence and fitness parameters. This allows healthcare companies to intervene the issues early, thus supporting aging in place. An article published on the website of the World Health Organization (WHO) shows that individuals aged over 60 are expected to double by 2050, reaching nearly 2.1 Billion worldwide. This is projected to positively impact the product demand while significantly boosting the connected drug delivery devices market growth.

Rising prevalence of chronic obstructive pulmonary disease (COPD)

As per the content updated in 2023 on the website of the World Health Organization (WHO), nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries. COPD patients require precise and managed delivery of medicinal drugs which include bronchodilators and corticosteroids. Connected drug delivery devices ensure correct dosing and timely administration, which is vital for coping with COPD signs effectively. In addition, connected devices can monitor inhalation strategies and provide feedback to patients in actual time. This allows COPD sufferers optimize their inhalation approach, making sure that they obtain the maximum benefits from their medicines. In line with this, COPD is a revolutionary disease that requires continuous monitoring of symptoms and lung function. Connected devices permit for remote monitoring of COPD patients' fitness fame, consisting of lung feature tests and symptom monitoring, facilitating early detection of exacerbations and timely adjustments to treatment plans.

Thriving telemedicine sector

The IMARC Group's report shows that the global telemedicine market reached USD 74.7 Billion in 2023. Telemedicine platforms facilitate remote consultations between healthcare providers and patients, offering greater accessibility and convenience for individuals seeking healthcare. Connected drug delivery devices supplement telemedicine by enabling real-time tracking of patients' medication adherence, treatment response, and overall health status. These devices provide vital data on drug intake, dosage timing, and patient condition, which is especially beneficial for managing chronic conditions such as diabetes, hypertension, and respiratory illnesses. Additionally, the integration of connected drug delivery devices with telehealth platforms allows healthcare providers to remotely adjust medication dosages, fine-tune treatment plans, and monitor patient progress continuously. This synergy not only ensures more accurate and personalized care but also enhances the effectiveness of telemedicine consultations by offering actionable insights directly from the patient's environment. Such integration supports proactive management and improves patient outcomes, reducing the need for frequent in-person visits.

Connected Drug Delivery Devices Industry Segmentation:

Analysis by Product:

  • Connected Sensors
    • Connected Inhaler Sensors
    • Connectable Injection Sensors
  • Integrated Connected Devices
    • Connected Inhalation Devices
    • Connected Injection Devices

Integrated connected devices hold the biggest market share, accounting 56.8% in 2024. Integrated connected devices (connected inhalation devices and connected injection devices) represent the largest segment attributed to their ability to combine medication delivery with advanced monitoring features, significantly enhancing patient care. These devices provide real-time tracking of medication usage, helping patients adhere to prescribed regimens and improving overall treatment outcomes. For instance, connected inhalers monitor usage frequency, technique, and dosage, while connected injection devices track injection sites, doses, and timing, offering valuable data for both patients and healthcare providers. The integration of sensors and connectivity allows for immediate feedback, helping to identify and address issues like missed doses, improper techniques, or potential side effects. Furthermore, these devices enable remote monitoring by healthcare professionals, facilitating personalized treatment adjustments. As a result, integrated connected devices offer a comprehensive solution that enhances convenience, precision, and patient engagement, driving their dominance in the market.

Analysis by End User:

  • Hospitals and Healthcare Providers
  • Homecare

Hospitals and healthcare providers stand as the largest component in 2024, holding 59.3% of the market share. Hospitals and healthcare providers lead the market because of their critical need for efficient patient care, improved medication adherence, and better treatment outcomes. These institutions rely on connected devices to streamline medication management, monitor patient progress, and enable more personalized treatments. With the growing prevalence of chronic diseases such as diabetes, asthma, and cardiovascular conditions, healthcare providers are adopting connected drug delivery systems to ensure accurate dosing and track medication usage in real time. The integration of connected devices into healthcare settings also supports remote monitoring, reducing the need for frequent hospital visits, and providing a more convenient and cost-effective solution for both patients and providers. Moreover, hospitals benefit from the real-time data provided by connected devices, which enhances decision-making and patient safety. As healthcare systems move toward more digital and data-driven approaches, hospitals and healthcare providers continue to drive demand for connected drug delivery technologies.

Analysis by Technology:

  • Bluetooth
  • NFC
  • Other Technologies

In 2024, Bluetooth represented the largest segment, accounting 61.8% of the market share. Bluetooth leads the market due to its numerous advantages in healthcare applications. Its low power usage is a critical factor, allowing devices such as insulin pens, inhalers, and wearable injectors to operate efficiently for long periods without frequent battery replacements, enhancing patient compliance and reducing operational costs. Bluetooth's wireless communication capabilities enable seamless data transmission between drug delivery devices and mobile applications or healthcare platforms, providing real-time insights into medication usage, dosage, and adherence. This capability is vital for remote monitoring, allowing healthcare providers to track patient progress and adjust treatment plans as needed. Additionally, Bluetooth is widely compatible with a range of devices, including smartphones, tablets, and other medical equipment, ensuring ease of integration into existing healthcare systems. The technology's reliability, security, and cost-effectiveness make Bluetooth a natural fit for the connected drug delivery device market, driving its widespread adoption globally.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share at 41.2%. North America dominates the market owing to the increasing healthcare expenditure. According to the information revised in 2023 on the Centers for Medicare & Medicaid Services website, U.S. health care expenditures increased by 4.1 percent in 2022, totaling USD 4.5 trillion or USD 13,493 for each individual. The rising healthcare spending indicates a stronger focus on enhancing patient results and lowering total healthcare expenses via innovative technologies. Besides this, the region has a strong presence of pharmaceutical companies and medical device manufacturers that are investing heavily in research and development (R&D) activities of connected drug delivery devices. These companies are leveraging advancements in IoT and digital connectivity to develop innovative devices that enhance medication adherence, patient monitoring, and overall treatment outcomes. Additionally, beneficial reimbursement policies and encouraging regulatory frameworks in the area aid in the swift expansion of this market segment.

Key Regional Takeaways:

United States Connected Drug Delivery Devices Market Analysis

In North America, the market share for the United States was 81.80% of the total. The adoption of connected drug delivery devices has surged, driven by increasing investments aimed at enhancing the healthcare infrastructure. For instance, U.S. healthcare companies securing venture capital deals of USD 15 Million plus are driving robust investment growth, focusing on innovation in medical technology to meet rising market demands. These devices enable real-time monitoring and improved medication adherence, appealing to both providers and patients. With more resources allocated to integrating advanced technologies, healthcare systems are better equipped to offer personalized treatment solutions. Such investments pave the way for the incorporation of connected solutions into clinical workflows, simplifying chronic disease management and reducing hospital readmissions. Patients benefit from timely alerts and dosage tracking, while healthcare providers gain access to valuable data that improves decision-making. Advanced connectivity features, combined with the demand for efficient patient care, are driving this shift. The growing focus on reducing long-term treatment costs and improving outcomes favoring the connected drug delivery devices market forecast.

Europe Connected Drug Delivery Devices Market Analysis

An aging population has significantly influenced the adoption of connected drug delivery devices, as these systems address the unique healthcare challenges of older adults. For instance, Europe's ageing population is on the rise, with one in five Europeans now aged 65 or older, projected to approach 30% by 2050. With age-related conditions requiring consistent and precise medication, such devices help ensure adherence to prescribed regimens. They simplify the administration process for individuals with limited mobility or cognitive decline by providing automated reminders and easy-to-use interfaces. Additionally, caregivers can remotely monitor medication schedules and adjust treatments as needed, enhancing the quality of care. This focus on supporting aging individuals fosters increased interest in technologies that improve independence and safety. Furthermore, healthcare providers benefit from access to detailed medication data, enabling them to identify trends and tailor therapies effectively. As the population continues to age, the demand for solutions that enhance patient care and reduce hospitalizations is driving the widespread adoption of these devices in managing chronic conditions.

Asia Pacific Connected Drug Delivery Devices Market Analysis

The rise of digitalization and telemedicine has fuelled the connected drug delivery devices market demand. For instance, Indian digital healthcare segment is estimated to grow 10x from USD 2.7 Billion in 2022 to USD 37 Billion by 2030. These devices seamlessly integrate with digital platforms, facilitating remote patient monitoring and enhanced medication adherence. As healthcare providers are continuously relying on telehealth solutions, the requirement for connected systems that bridge the gap between patients and caregivers has become more pronounced. Digital ecosystems now include features that allow users to share medication data with professionals in real-time, streamlining treatment processes. Patients benefit from reminders and data tracking, while caregivers can monitor compliance remotely. This digital evolution has transformed the way chronic diseases are managed, emphasizing convenience and accessibility. With the growing emphasis on telemedicine, connected devices are becoming indispensable tools in ensuring continuity of care and improving therapeutic outcomes, particularly in areas that rely heavily on virtual healthcare models.

Latin America Connected Drug Delivery Devices Market Analysis

Chronic obstructive pulmonary disease is a significant factor driving the use of connected drug delivery devices. For instance, among the 22,663,091 deaths that occurred from 2000 to 2019 in Brazil, 1,132,968 had COPD mentioned as a cause of death. These devices provide patients with real-time feedback and reminders, ensuring consistent use of prescribed treatments. By monitoring inhaler usage and patterns, the devices help optimize medication adherence, leading to improved outcomes. For healthcare providers, the ability to track usage remotely offers insights into disease progression and effectiveness of treatments. This connectivity facilitates timely interventions, reducing exacerbations and hospital visits. The increased awareness of managing respiratory conditions with precision and ease makes these devices a preferred choice for long-term care, aligning with the growing focus on effective management of chronic diseases.

Middle East and Africa Connected Drug Delivery Devices Market Analysis

The expansion of healthcare facilities has bolstered the adoption of connected drug delivery devices, addressing the need for advanced patient-centric solutions. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. These devices integrate seamlessly into hospital and clinic settings, providing real-time data to enhance treatment accuracy. Their ability to simplify medication management while reducing errors aligns with the objectives of modern healthcare environments. Patients benefit from enhanced compliance tools, while professionals utilize the collected data for informed decision-making. As healthcare systems evolve, incorporating connected devices ensures streamlined operations and improved patient experiences. This growth reflects the increasing emphasis on leveraging technology to optimize care delivery in expanding medical infrastructures.

Competitive Landscape:

Major participants in the market are concentrating on technological advancement and strategic collaborations to enhance their product range. Organizations are putting substantial resources into creating sophisticated features, including real-time tracking, data analysis, and compatibility with mobile apps, to boost patient involvement and enhance treatment results. They are prioritizing obtaining regulatory approvals to ensure their devices comply with industry standards and achieve wider market acceptance. Moreover, numerous stakeholders are partnering with healthcare providers, technology firms, and regulatory agencies to facilitate the integration of connected devices in diverse healthcare environments. In 2024, Medtronic revealed that its Simplera(TM) continuous glucose monitor (CGM) received FDA approval, offering a compact, integrated device. Medtronic announced a worldwide collaboration with Abbott to combine Abbott's CGM technology with Medtronic's intelligent insulin delivery systems. This partnership seeks to improve access to sophisticated diabetes management resources.

The report provides a comprehensive analysis of the competitive landscape in the connected drug delivery devices market with detailed profiles of all major companies, including:

  • Adherium Ltd.
  • BioCorp Production
  • Cohero Health Inc. (AptarGroup Inc.)
  • Elcam Medical ACS. Ltd
  • Findair Sp. z o. o.
  • Merck KGaA
  • Phillips Medisize (Molex LLC)
  • Propeller Health (Resmed Inc.)
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services Inc.

Key Questions Answered in This Report

  • 1.How big is the connected drug delivery devices market?
  • 2.What is the expected growth rate of the global connected drug delivery devices market during 2025-2033?
  • 3.What are the factors driving the connected drug delivery devices market?
  • 4.What are the key regions in the global connected drug delivery devices market?
  • 5.Who are the key players/companies in the global connected drug delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Connected Drug Delivery Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Connected Sensors
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Connected Inhaler Sensors
      • 6.1.2.2 Connectable Injection Sensors
    • 6.1.3 Market Forecast
  • 6.2 Integrated Connected Devices
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Connected Inhalation Devices
      • 6.2.2.2 Connected Injection Devices
    • 6.2.3 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals and Healthcare Providers
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Homecare
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Bluetooth
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 NFC
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Other Technologies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adherium Limited
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 BioCorp Production
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Cohero Health Inc. (AptarGroup Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Elcam Medical ACS. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Findair Sp. z o. o.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck KGaA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Phillips Medisize (Molex LLC)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Propeller Health (Resmed Inc.)
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Teva Pharmaceutical Industries Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 West Pharmaceutical Services Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Connected Drug Delivery Devices Market: Major Drivers and Challenges
  • Figure 2: Global: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Connected Drug Delivery Devices Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Connected Drug Delivery Devices Market: Breakup by End User (in %), 2024
  • Figure 6: Global: Connected Drug Delivery Devices Market: Breakup by Technology (in %), 2024
  • Figure 7: Global: Connected Drug Delivery Devices Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Connected Drug Delivery Devices (Connected Sensors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Connected Drug Delivery Devices (Connected Sensors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Connected Drug Delivery Devices (Integrated Connected Devices) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Connected Drug Delivery Devices (Integrated Connected Devices) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Connected Drug Delivery Devices (Hospitals and Healthcare Providers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Connected Drug Delivery Devices (Hospitals and Healthcare Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Connected Drug Delivery Devices (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Connected Drug Delivery Devices (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Connected Drug Delivery Devices (Bluetooth) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Connected Drug Delivery Devices (Bluetooth) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Connected Drug Delivery Devices (NFC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Connected Drug Delivery Devices (NFC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Connected Drug Delivery Devices (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Connected Drug Delivery Devices (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: North America: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: North America: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: United States: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: United States: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Canada: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Canada: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Asia-Pacific: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Asia-Pacific: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: China: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: China: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Japan: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Japan: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: India: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: India: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: South Korea: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: South Korea: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Australia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Australia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Indonesia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Indonesia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Europe: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Europe: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Germany: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Germany: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: France: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: France: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: United Kingdom: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: United Kingdom: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Italy: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Italy: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Spain: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Spain: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Russia: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Russia: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Latin America: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Latin America: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Brazil: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Brazil: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Mexico: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Mexico: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Middle East and Africa: Connected Drug Delivery Devices Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Middle East and Africa: Connected Drug Delivery Devices Market: Breakup by Country (in %), 2024
  • Figure 70: Middle East and Africa: Connected Drug Delivery Devices Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Global: Connected Drug Delivery Devices Industry: SWOT Analysis
  • Figure 72: Global: Connected Drug Delivery Devices Industry: Value Chain Analysis
  • Figure 73: Global: Connected Drug Delivery Devices Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Connected Drug Delivery Devices Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Connected Drug Delivery Devices Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 4: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 5: Global: Connected Drug Delivery Devices Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Connected Drug Delivery Devices Market: Competitive Structure
  • Table 7: Global: Connected Drug Delivery Devices Market: Key Players